State- and Use-dependent Block of Muscle Nav1.4 and Neuronal Nav1.7 Voltage-gated Na+ Channel Isoforms by Ranolazine
Overview
Pharmacology
Authors
Affiliations
Ranolazine is an antianginal agent that targets a number of ion channels in the heart, including cardiac voltage-gated Na(+) channels. However, ranolazine block of muscle and neuronal Na(+) channel isoforms has not been examined. We compared the state- and use-dependent ranolazine block of Na(+) currents carried by muscle Nav1.4, cardiac Nav1.5, and neuronal Nav1.7 isoforms expressed in human embryonic kidney 293T cells. Resting and inactivated block of Na(+) channels by ranolazine were generally weak, with a 50% inhibitory concentration (IC(50)) >/= 60 microM. Use-dependent block of Na(+) channel isoforms by ranolazine during repetitive pulses (+50 mV/10 ms at 5 Hz) was strong at 100 microM, up to 77% peak current reduction for Nav1.4, 67% for Nav1.5, and 83% for Nav1.7. In addition, we found conspicuous time-dependent block of inactivation-deficient Nav1.4, Nav1.5, and Nav1.7 Na(+) currents by ranolazine with estimated IC(50) values of 2.4, 6.2, and 1.7 microM, respectively. On- and off-rates of ranolazine were 8.2 microM(-1) s(-1) and 22 s(-1), respectively, for Nav1.4 open channels and 7.1 microM(-1) s(-1) and 14 s(-1), respectively, for Nav1.7 counterparts. A F1579K mutation at the local anesthetic receptor of inactivation-deficient Nav1.4 Na(+) channels reduced the potency of ranolazine approximately 17-fold. We conclude that: 1) both muscle and neuronal Na(+) channels are as sensitive to ranolazine block as their cardiac counterparts; 2) at its therapeutic plasma concentrations, ranolazine interacts predominantly with the open but not resting or inactivated Na(+) channels; and 3) ranolazine block of open Na(+) channels is via the conserved local anesthetic receptor albeit with a relatively slow on-rate.
Ranolazine Attenuates Brain Inflammation in a Rat Model of Type 2 Diabetes.
Cassano V, Tallarico M, Armentaro G, De Sarro C, Iannone M, Leo A Int J Mol Sci. 2022; 23(24).
PMID: 36555798 PMC: 9782607. DOI: 10.3390/ijms232416160.
Rouhana S, Virsolvy A, Fares N, Richard S, Thireau J Pharmaceuticals (Basel). 2022; 15(1).
PMID: 35056088 PMC: 8777683. DOI: 10.3390/ph15010031.
Chuang T, Cho H, Wu S Biomedicines. 2022; 10(1).
PMID: 35052766 PMC: 8773265. DOI: 10.3390/biomedicines10010086.
Block of Voltage-Gated Sodium Channels as a Potential Novel Anti-cancer Mechanism of TIC10.
Fuchs E, Messerer D, Karpel-Massler G, Fauler M, Zimmer T, Jungwirth B Front Pharmacol. 2021; 12:737637.
PMID: 34744721 PMC: 8567104. DOI: 10.3389/fphar.2021.737637.
Desaphy J, Altamura C, Vicart S, Fontaine B J Neuromuscul Dis. 2020; 8(3):357-381.
PMID: 33325393 PMC: 8203248. DOI: 10.3233/JND-200582.